We are focusing on neuropsychiatric disorders where there is a high unmet need for additional treatment options. Sage is working to understand the underlying mechanisms for numerous disorders of the brain and central nervous system (CNS) to help us develop therapies that may address current treatment gaps for patients.
We are using our unique development approach to systemically evaluate our drug candidates in a range of neuropsychiatric disorders:
Dementia, including Alzheimer’s disease and a broad spectrum of other forms, affects more than 36 million people worldwide. This neurodegenerative disorder is characterized by a decline in cognitive function. Evidence suggests that enhancing the excitatory NMDA pathway in the brain could work to treat several kinds of dementia. Researchers have found elevated anti-NMDA antibodies in many people with dementia.
Huntington’s disease is a rare, progressive, inherited neurodegenerative disease with more than 30,000 diagnosed patients in the U.S. Symptoms appear typically at ages 30–45 and progress over 15–20 years, leading to death in all cases. Huntington’s disease is associated with lower levels of cerebrosterol, a natural positive modulator of NMDA receptor activity.